RESUMO
OBJECTIVE: Examine prevalence and level of suicide risk, and its associations with sociodemographic factors and mood disorders. METHODS: A cross-sectional study with a random sample of 530 individuals aged 60 years or more from Family Health Strategy of Porto Alegre, Brazil. Diagnosis was made by psychiatrists using the Mini International Neuropsychiatric Interview plus (MINIplus). RESULTS: Suicide risk was found in 15.7% of the sample. Female gender, elderly with no income or with no paid activity and those who have lost one or more of his sons presented association with suicide risk. Bipolar disorder shows association with suicide risk for those with or without current episode. For unipolar depression only elderly with a current episode shows association with suicide risk. LIMITATIONS: The cross-sectional design limits the examination of causative relationships. The MINIplus questions are not broad enough to assess other important self-destructive behaviors. CONCLUSIONS: A high rate of suicide risk was found. As expected an increased rate of mood disorders were related to the risk of suicide. The loss of sons may partly explain a subtype of late-life risk of suicide or mood disorders especially in the oldest-old. These findings can be a useful to generate other research hypothesis and for health professionals who care older persons. Detecting characteristics linked to suicide, therefore opening up the possibility of preventing tragic outcomes providing a proper treatment.
Assuntos
Suicídio/estatística & dados numéricos , Idoso , Idoso de 80 Anos ou mais , Transtorno Bipolar/epidemiologia , Transtorno Bipolar/psicologia , Brasil/epidemiologia , Estudos Transversais , Transtorno Depressivo/epidemiologia , Transtorno Depressivo/psicologia , Feminino , Humanos , Renda/estatística & dados numéricos , Entrevista Psicológica , Masculino , Pessoa de Meia-Idade , Transtornos do Humor/epidemiologia , Transtornos do Humor/psicologia , Prevalência , Fatores de Risco , Fatores Sexuais , Ideação Suicida , Suicídio/psicologia , Tentativa de Suicídio/psicologia , Tentativa de Suicídio/estatística & dados numéricos , Desemprego/psicologiaRESUMO
PURPOSE: To compare the therapeutic effect of rimonabant, a new drug which is a selective antagonist of CB1 receptors, with the sibutramine. METHODS: It is an experimental clinical trial, prospective, placebo controlled. Our test was performed in 38 rats, adults females with a hyper caloric diet. We collected their blood 3 times and weighted them once a week. We divided the rats in 3 groups: Rimonabant, Sibutramine and Control. Statistic analysis has been made through ANOVA test, Tukey test and t Student test. RESULTS: The Rimonabant group demonstrated a significant reduction of the weight increase in rats. The Sibutramine group showed a significant reduction on blood glycemia compared to Rimonabant group and Control group. CONCLUSIONS: Rimonabant showed to be more effective than Sibutramine by decreasing weight gain. Sibutramine has been more effective than Rimonabant and Control groups by decreasing the blood glycemia.
Assuntos
Depressores do Apetite/farmacologia , Glicemia/metabolismo , Peso Corporal/efeitos dos fármacos , Ciclobutanos/farmacologia , Gorduras na Dieta/administração & dosagem , Piperidinas/farmacologia , Pirazóis/farmacologia , Animais , Glicemia/efeitos dos fármacos , Comportamento Compulsivo/metabolismo , Métodos Epidemiológicos , Feminino , Modelos Animais , Ratos , Ratos Wistar , Rimonabanto , Aumento de Peso/efeitos dos fármacosRESUMO
PURPOSE: To compare the therapeutic effect of rimonabant, a new drug which is a selective antagonist of CB1 receptors, with the sibutramine. METHODS: It is an experimental clinical trial, prospective, placebo controlled. Our test was performed in 38 rats, adults females with a hyper caloric diet. We collected their blood 3 times and weighted them once a week. We divided the rats in 3 groups: Rimonabant, Sibutramine and Control. Statistic analysis has been made through ANOVA test, Tukey test and t Student test. RESULTS: The Rimonabant group demonstrated a significant reduction of the weight increase in rats. The Sibutramine group showed a significant reduction on blood glycemia compared to Rimonabant group and Control group. CONCLUSIONS: Rimonabant showed to be more effective than Sibutramine by decreasing weight gain. Sibutramine has been more effective than Rimonabant and Control groups by decreasing the blood glycemia.
OBJETIVO: Comparar o efeito do rimonabanto, nova droga seletivamente antagonista dos receptores CB1, com a sibutramina. MÉTODOS: Ensaio clínico experimental, prospectivo, placebo controlado. Realizado com 38 ratas, adultas, submetidas a dieta hipercalórica. Foram coletadas 3 amostras de sangue e o peso controlado semanalmente. Foram divididas em 3 grupos: Rimonabanto, Sibutramina e Controle. Analise estatística realizada com ANOVA, teste t de Student e teste de Tukey. RESULTADOS: O grupo Rimonabanto obteve redução significante do ganho de peso. O grupo Sibutramina teve redução significativa da glicemia quando comparado aos demais grupos. CONCLUSÕES: Rimonabanto foi mais efetivo que a Sibutramina na redução do ganho de peso. A Sibutramina foi mais efetiva na redução da glicemia do que os grupos controle e Rimonabanto.
Assuntos
Animais , Feminino , Ratos , Depressores do Apetite/farmacologia , Glicemia/metabolismo , Peso Corporal/efeitos dos fármacos , Ciclobutanos/farmacologia , Gorduras na Dieta/administração & dosagem , Piperidinas/farmacologia , Pirazóis/farmacologia , Glicemia/efeitos dos fármacos , Comportamento Compulsivo/metabolismo , Métodos Epidemiológicos , Modelos Animais , Ratos Wistar , Aumento de Peso/efeitos dos fármacosRESUMO
PURPOSE: To compare the therapeutic effect of rimonabant, a new drug which is a selective antagonist of CB1 receptors, with the sibutramine. METHODS: It is an experimental clinical trial, prospective, placebo controlled. Our test was performed in 38 rats, adults females with a hyper caloric diet. We collected their blood 3 times and weighted them once a week. We divided the rats in 3 groups: Rimonabant, Sibutramine and Control. Statistic analysis has been made through ANOVA test, Tukey test and t Student test. RESULTS: The Rimonabant group demonstrated a significant reduction of the weight increase in rats. The Sibutramine group showed a significant reduction on blood glycemia compared to Rimonabant group and Control group. CONCLUSIONS: Rimonabant showed to be more effective than Sibutramine by decreasing weight gain. Sibutramine has been more effective than Rimonabant and Control groups by decreasing the blood glycemia.(AU)
OBJETIVO: Comparar o efeito do rimonabanto, nova droga seletivamente antagonista dos receptores CB1, com a sibutramina. MÉTODOS: Ensaio clínico experimental, prospectivo, placebo controlado. Realizado com 38 ratas, adultas, submetidas a dieta hipercalórica. Foram coletadas 3 amostras de sangue e o peso controlado semanalmente. Foram divididas em 3 grupos: Rimonabanto, Sibutramina e Controle. Analise estatística realizada com ANOVA, teste t de Student e teste de Tukey. RESULTADOS: O grupo Rimonabanto obteve redução significante do ganho de peso. O grupo Sibutramina teve redução significativa da glicemia quando comparado aos demais grupos. CONCLUSÕES: Rimonabanto foi mais efetivo que a Sibutramina na redução do ganho de peso. A Sibutramina foi mais efetiva na redução da glicemia do que os grupos controle e Rimonabanto.(AU)